Thomas A. Fitzgerald - 01 Mar 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Financial Officer, Director
Signature: /s/ Thomas A. Fitzgerald
Issuer symbol: RNAZ
Transactions as of: 01 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2022, 17:12:42 UTC
Previous filing: 03 Feb 2022
Next filing: 17 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNAZ	Stock Option (Right to Buy)	Award	$0	+52,000		$0.000000	52,000	01 Mar 2022	Common Stock	52,000	$2.12	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining Stock Options shall vest and become exercisable in twenty-four (24) equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.

Content

Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (February 1, 2022). Thereafter, the remaining Stock Options shall vest and become exercisable in twenty-four (24) equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.